Abstract
Plasmodium vivax Duffy binding protein region II (DBPII) is an essential ligand for reticulocyte invasion, thereby making this molecule an attractive vaccine candidate against asexual blood-stage P. vivax. Similar to other Plasmodium blood-stage vaccine candidates, strain-specific immunity due to DBPII allelic variation may complicate vaccine efficacy. Targeting immune responses to more conserved epitopes that are potential targets of strain-transcending neutralising immunity is necessary to avoid induction of strain-specific responses to dominant variant epitopes. In this article, we focus on different approaches to optimise the design of DBP immunogenicity to target conserved epitopes, which is important for developing a broadly effective vaccine against P. vivax.
Copyright © 2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Amino Acid Sequence
-
Antibodies, Protozoan / immunology*
-
Antigens, Protozoan / chemistry*
-
Antigens, Protozoan / genetics
-
Antigens, Protozoan / immunology*
-
Antigens, Protozoan / metabolism
-
Binding Sites, Antibody
-
Epitopes / genetics
-
Epitopes / immunology
-
Humans
-
Malaria Vaccines* / genetics
-
Malaria Vaccines* / immunology
-
Malaria, Vivax / immunology
-
Malaria, Vivax / parasitology
-
Malaria, Vivax / prevention & control*
-
Plasmodium vivax / genetics
-
Plasmodium vivax / immunology*
-
Polymorphism, Genetic
-
Protozoan Proteins / chemistry*
-
Protozoan Proteins / genetics
-
Protozoan Proteins / immunology*
-
Protozoan Proteins / metabolism
-
Receptors, Cell Surface / chemistry*
-
Receptors, Cell Surface / genetics
-
Receptors, Cell Surface / immunology*
-
Receptors, Cell Surface / metabolism
Substances
-
Antibodies, Protozoan
-
Antigens, Protozoan
-
Duffy antigen binding protein, Plasmodium
-
Epitopes
-
Malaria Vaccines
-
Protozoan Proteins
-
Receptors, Cell Surface